Brown, David A.
Perry, Justin B.
Allen, Mitchell E.
Sabbah, Hani N.
Stauffer, Brian L.
Shaikh, Saame Raza
Cleland, John G. F.
Colucci, Wilson S.
Butler, Javed
Voors, Adriaan A.
Anker, Stefan D.
Pitt, Bertram
Pieske, Burkert
Filippatos, Gerasimos
Greene, Stephen J.
Gheorghiade, Mihai
Article History
First Online: 22 December 2016
Competing interests
: D.A.B. has received consulting income from Stealth BioTherapeutics. J.G.F.C. reports consultation with Amgen, Biotronik, GSK, Medtronic, Novartis, Servier, Sorin, and Stealth BioTherapeutics. W.S.C. is a consultant to BMS, Cardioxyl, Johnson & Johnson, Mast, Merck, and Novartis. J.B. is a consultant to Amgen, Bayer, Boehringer Ingelheim, Cardiocell, Celladon, Novartis, Relypsa, Trevena, Z Pharma, and Zensun. A.A.V. has received consultancy fees and/or research grants from Alere, Amgen, Bayer, Boehringer, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, Servier, Singulex, Sphingotec, Trevena, Vifor, and ZS Pharma. B.Pieske reports speaker's bureau and/or advisory/steering committee honoraria from Abbott Vascular, AstraZeneca, Bayer Healthcare, Novartis Pharma, Servier, and Stealth BioTherapeutics. M.G. has been a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer HealthCare, CorThera, Cytokinetics, DebioPharm, Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Johnson & Johnson, Medtronic, Merck, Novartis Pharma, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Takeda Pharmaceutical, and Trevena Therapeutics. The other authors declare no competing interests.